However, at least four randomized phase III trials have been completed, and none of these trials appear to show a benefit from using these drugs in AML patients. [14] [15] [16] [17] In contrast, there has been one strikingly positive trial from the Southwest Oncology Group (SWOG), treating patients with poor-risk relapsed AML with cytarabine (ara-C) and concomitant daunorubicin and CSA. 18 CSA affects drug resistance by inhibiting Pgp (Mdr1)-mediated efflux of chemotherapeutic drugs, as well as through possible immune and antiapoptotic mechanisms. 19, 20 When CSA was used after high-dose ara-c and concurrently with daunorubicin in this SWOG phase III trial for relapsed AML, there was a highly significant increase in the complete response (CR) rate, the disease-free survival (DFS), and overall survival (OS). 18 The daunorubicin was given by continuous intravenous infusion, which may be one of the important differences between this and most of the other MDR modulation trials.
The frequency of MDR expression in AML increases with age and is predictive of poor outcome with respect to CR, DFS, and OS. [21] [22] [23] [24] [25] Approximately two out of three patients with AML over the age of 60 years have high levels of MDR1 expression, whereas it is less commonly seen in younger patients. MDR is also overexpressed in AML that follows a myelodysplastic syndrome (MDS). We have been pursuing the hypothesis that MDR1 positive clonogenic AML blasts may form a reservoir of drug-resistant cells that contribute to treatment failure, which means that even when the bulk of AML cells do not appear to express MDR1, the clonogenic AML cell does. Therefore, that minority cell population should be the real target for these studies. If the therapy were successful, the benefit should be seen not necessarily in the CR rate but rather in the DFS or in the time to relapse. One of the difficulties with the first generation of MDR modulation trials was that they were directed toward patients who had high levels of MDR via multiple mechanisms. The benefit of inhibition of Pgp-mediated drug efflux in older patients or those with relapsed AML may have been obscured by other factors associated with drug resistance, including adverse cytogenetics and myelodysplasia. These and other mechanisms of drug resistance are unlikely to be affected by Pgp inhibitors alone.
PSC833 is a nonimmunosuppressive cyclosporine analogue that is 5-30 times more potent than CSA as a Pgp inhibitor in vitro. Data from the Cancer and Leukemia Group B (CALGB) clinical trials using PSC833 as an MDR inhibitor suggest that there is a need to refine the target population, both among patient subsets as well as on a cellular basis. The strategy of MDR modulation will likely not suit all patients, but there may be subsets of patients who will benefit from this approach. Second-and third-generation MDR modulators will hopefully demonstrate more benefit and less toxicity. [26] [27] [28] The CALGB 9621 study used parallel phase I dose escalation trials to develop remission induction regimens for AML patients under the age of 60 years, which included two agents that are substrates for Pgp. 29, 30 Both daunorubicin and etoposide are effluxed from cells by membrane active mechanisms. 31 The ADE regimen (ara-C, daunorubicin, and etoposide) consisted of ara-C maintained at a constant infusion rate of 100 mg/m 2 /d for 7 days with daunorubicin escalated stepwise from 60 mg/m 2 for 3 days to 95 mg/m 2 , and then lowered to 90 mg/m 2 in the final cohort. The dose of etoposide was escalated from 100 mg/m 2 /d to 150 mg/m 2 for 3 days and then lowered to 100 mg/m 2 /d for the final dose cohort, based on toxicity. The final doses here are the doses that were subsequently chosen for the current phase III trial (CALGB 19808) . At the same time, a parallel schedule of ADEP (ara-C, daunorubicin, etoposide, and PSC833) was developed in the same fashion. The PSC833 was given with a loading dose of 2.8 mg/kg followed by a continuous infusion with 10 mg/kg/d over 72 h, overlapping with the period of time when daunorubicin and etoposide were being infused. The ara-C had the same dose and schedule as in the ADE regimen. The daunorubicin was escalated starting at 40, then 45, and finally to 50 mg/m 2 /d, but eventually had to be lowered to 40 mg/m 2 /d because of toxicity. The etoposide dose was de-escalated from 60 to 40 mg/m 2 /d for 3 days. Overall, we treated 207 patients with the ADE regimen and 201 patients with the ADEP regimen in 22 separate treatment cohorts in order to derive these regimens with a dose-limiting toxicity under 30% of patients. 30 The overall CR rates were 79% for ADE and 72% for ADEP, taking together all the different dosing cohorts. Of those who achieved a CR, 84% came after the first course of ADE and 94% after the first course of ADEP. A second course produced 60% CRs after ADE but only 29% after ADEP. Thus, for patients who did not go into remission after the first exposure to ADEP, there was a relatively low response rate after a second course of therapy. There was, however, some additional benefit from the second course of induction therapy using the ADE regimen.
Daunorubicin or etoposide pharmacokinetics or steady-state levels were not measured during these trials, but a clinical end point was chosen instead. Drugs were escalated until equivalent, but still acceptable, toxicities were observed with the two regimens. Dose-limiting toxicities were predominantly grade 4 mucositis and reversible hepatotoxicity, which occurred in about 11% of patients receiving ADE compared to 22% of patients receiving ADEP at the final doses chosen for the phase III trial. If all of the deaths that occurred within 60 days from the start of the study were included (17% for ADE and 22% for ADEP), the induction toxicities were relatively equivalent between these two regimens. Since both efflux and excretion of daunorubicin and etoposide were inhibited by PSC833, the chemotherapy doses in the ADEP regimen had to be reduced by approximately half to provide acceptable toxicity (ADE: daunorubicin 90 mg/m An analysis of the outcomes following remission induction with ADEP and ADE showed no difference in OS (median survival, 1.3 years for both). However, the CALGB 9621 study was not a randomized trial; some of these patients were treated at slightly more toxic levels and some at slightly less effective concentrations of daunorubicin and etoposide. An analysis of DFS between patients treated with the PSC833-containing regimen (median, 1.2 years) compared to those who received higher doses of daunorubicin and etoposide without PSC833 (0.8 years) showed statistical significance in favor of patients who received PSC833 (P ¼ 0.04). In patients under the age of 45 years, in whom MDR1 is generally not highly expressed in the bulk of AML cells, there was a statistically significant advantage in DFS favoring patients who received PSC833 (median for ADEP, 1.4 years; for ADE, 0.7 years; P ¼ 0.004).
Based on this favorable outcome, a phase III randomized comparison (CALGB 19808) was initiated in November 2000. During the remission induction period, newly diagnosed patients less than 60 years old are randomized to ADE or ADEP at the doses that were developed in the CALGB 9621 trial. Postremission therapy is delivered with risk-adapted intensification based on cytogenetics. 32 Those patients who have a core binding factor type of leukemia (17% in our experience) receive postremission therapy with three courses of high-dose cytarabine (HiDAC) given in the CALGB fashion. All other patients, including those with normal cytogenetics, are assigned to receive an autologous stem cell transplant in first remission. 33 Later, a second randomization assigns patients either to no further therapy (observation) or to 90 days of interleukin-2 (IL-2) therapy. 34 CALGB studies 9420 and 9720 pursued a similar strategy of MDR modulation with PSC833 in AML patients over the age of 60 years. 17, 35 Treatment regimens were developed using a similar dose escalation/de-escalation scheme. The final doses of daunorubicin (60 mg/m 2 ) and etoposide (100 mg/m 2 ) together with ara-C, or daunorubicin (40 mg/m 2 ) and etoposide (60 mg/ m 2 ) and ara-C with PSC833 appeared to give equal degrees of toxicity in the dose escalation pilot study, CALGB 9420. 35 In the pilot study, we observed a 40% CR rate among patients receiving ADE and a 50% CR rate among patients receiving ADEP with an acceptable degree of toxicity and an induction death rate of less than 20%.
Based on these results, a phase III study was undertaken. The final data from the CALGB 9720 phase III study were recently presented at the American Society of Hematology meeting. 17 Newly diagnosed AML patients over the age of 60 years were randomly assigned to either the ADE or the ADEP arm. Those who achieved a CR received one course of consolidation therapy with the same treatment and, again, there was a second randomization where we explored the issue of postremission recombinant IL-2 therapy. However, unlike the phase I study, patients with a prior history of MDS and patients with mild impairment of renal and hepatic function were eligible for the phase III trial. After the first 120 patients were randomized to this study, a higher than expected induction death rate was observed on the experimental ADEP arm, and this arm was closed to further accrual. Of the first 120 patients, the median age was 70 years (range, 60-84 years) and 27% had a known history of MDS. Many of the AML de novo patients who enrolled also had multilineage dysplasia when they first presented with AML. Equivalent numbers were randomized to each treatment group, and there appeared to be no significant differences between the two groups in terms of disease characteristics. The CR rate on the standard ADE arm was 46%, slightly better than had been observed in the pilot study, but the CR rate on the ADEP arm (39%) was lower than anticipated. The induction death rate was 44% on the ADEP arm compared to 20% on the ADE arm. Previous CALGB studies that may have enrolled a slightly healthier group of elderly patients had reported an induction death rate of 25-30% in this older population. [36] [37] [38] Of note, there was no significant difference in the OS or DFS between the groups. Survival at 12 months was approximately 33% in both groups. Measuring drug efflux from these AML blast cells using the efflux of fluorescent dyes 3, 3 0 diethyloxacarbocyanine iodide (DiOC 2 (3)) and rhodamine indicated that about two-thirds of these older patients did show efflux that could be inhibited by PSC833, and one-third of patients did not have inhibitable efflux of daunorubicin or of DiOC 2 (3). 17, 39, 40 The CR rate was 91% in the small number of patients studied whose cells did not efflux anthracycline-like drugs and who had received the ADE regimen. This was significantly higher than the 41% CR rate seen with the same treatment in the efflux positive patients (P ¼ 0.03). However, there was no better outcome among the efflux positive patients who had received ADEP, and this lack of improvement may have been because of the added toxicity of the PSC833. At the same time, the CR rate (50%) among the efflux-negative patients on the ADEP arm was less than that seen on the ADE arm (91%). Whether this was related to increased toxicity, or to small numbers of patients studied, or to the reduced doses of daunorubicin and etoposide (with PSC833) used to treat this group is uncertain.
In conclusion, there was a high CR rate in the efflux-negative patients receiving ADE, suggesting that dose intensification using daunorubicin at 60 mg/m 2 and etoposide at 100 mg/m 2 with ara-C may be effective in older patients with drug-sensitive cells. If this group of patients could be identified rapidly at diagnosis, ADE would be a good induction regimen for these patients and there might be no advantage to adding PSC833. The similar CR rates observed in the efflux-positive patients regardless of receiving ADE or ADEP may reflect increased toxicity from PSC833 as well as the presence of additional resistance mechanisms in older patients. It is notable, however, that there was a longer DFS in the patients who received the MDR modulator. The next generation of randomized clinical trials will provide important information regarding MDR modulation strategies in AML.
